Clostridium difficile infection (‘CDI’) is a major healthcare issue in hospitals, long-term care homes, and increasingly in the wider community. It is a serious illness caused by infection of the colon by the bacteria, C. difficile, which produces toxins that cause inflammation, severe diarrhoea and can in the most serious of cases be fatal.Read More
30th September – 4th October 2015
Click to view the data presented on Phase 1b trial of SMT C1100 in DMD patients, and outline of Phase 2 proof of concept trial plans
17th-21st September 2015
Click to view the new preclincial data on CDI antibiotic SMT19969 at ICAAC 2015
Duchenne Muscular Dystrophy (‘DMD’) is a fatal, genetic disease that predominantly affects boys. It has a population of around 50,000 in the developed world and is classified as a rare or orphan disease. DMD is caused by the absence of a protein called dystrophin which is essential in maintaining the healthy function of muscles in the body.
Currently there is no disease modifying treatment for all patients with DMD.Read More